CGNSF - Cognetivity Neurosciences Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1720
-0.0008 (-0.49%)
At close: 1:52PM EST
Stock chart is not supported by your current browser
Previous Close0.1728
Open0.1720
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1720 - 0.1720
52 Week Range0.0641 - 0.3920
Volume2,030
Avg. Volume63,003
Market Cap7.8M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0850
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    Former Chief Executive of AXA PPP healthcare Keith Gibbs joins advisory board at Cognetivity Neurosciences

    VANCOUVER , Nov. 13, 2019 /CNW/ - Cognetivity Neurosciences Ltd. (the "Company" or "Cognetivity") (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced the appointment of Keith Gibbs , former Chief Executive of AXA PPP healthcare, to its advisory board with immediate effect. Gibbs retired from AXA PPP healthcare last December after 17 years as Chief Executive. During this time, he served on the board of AXA UK and a number of its other subsidiaries, including AXA Insurance, AXA Wealth and AXA Sun Life.

  • CNW Group

    Cognetivity Neurosciences achieves enrollment threshold for clinical evaluation study, enabling registration of ICA platform for CE marking

    OTCQB: CGNSF) today confirmed that it has assessed sufficient participants in the clinical evaluation study of its Integrated Cognitive Assessment (ICA) platform to register for CE marking. "We're extremely satisfied to have passed this critical milestone in the commercial development of our technology," said Cognetivity's CEO, Dr Sina Habibi .

  • CNW Group

    Cognetivity Neurosciences Announces Major Grant Award

    Cognetivity Neurosciences Announces Major Grant Award

  • CNW Group

    Cognetivity Neurosciences announces significant expansion of its UK NHS based clinical trial centers

    OTCQB: CGNSF) has confirmed positive progress in the clinical validation and commercial development of its cognitive assessment platform. Over the last six months, Cognetivity has achieved considerable expansion in its clinical recruitment base by establishing research affiliations with a number of additional institutions. It is now working in collaboration with the UK National Health Service (NHS) across ten sites, including South London & Maudsley (SLaM) and Sussex Partnership NHS Foundation Trusts, recently ranked as the top two mental health trusts for research activity in England by the National Institute for Health Research (NIHR).

  • CNW Group

    Cognetivity Neurosciences Arranges Convertible Notes

    OTCQB: CGNSF) announced that the Company has entered into a convertible loan agreement with the CEO and Director of the Company and issued a convertible note (the "Note") in the aggregate principal amount of C$164,110 . The Note bearing interest at 8% per annum, matures 12 months from the date of issuance (the "Maturity Date"). At any time prior to the Maturity Date on at least 10 days prior written notice to the Company, the lender may, in its sole discretion, elect to convert all, but not less than all, of the principal amount, all accrued and unpaid interest and all other amounts due by the Company to the lender pursuant to the Note (the "Indebtedness") into a number of units of the Company (the "Units") equal to the quotient of the Indebtedness and C$0.13 .  Each Unit will be comprised of one common share of the Company (a "Share") and one share purchase warrant (a "Warrant") of the Company.

  • CNW Group

    Cognetivity Neurosciences to Present Key Research Data Demonstrating its AI Platform's Unique Ability to Accurately Detect & Monitor Cognitive Impairment in Multiple Sclerosis Patients

    OTCQB: CGNSF) announced that results from its research into the use of the company's Integrated Cognitive Assessment in the detection of early stage cognitive impairment associated with Multiple Sclerosis (MS) are to be presented at the 35th congress of the European Committee For Treatment and Research In Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden . The presentation will be at 12:15 on the 13th of September 2019 at Stockholmsmässan, 125 80 Stockholm, Sweden .

  • CNW Group

    Cognetivity Neurosciences' Early Stage Dementia Detection Technology Profiled in Digital Health

    OTCQB: CGNSF) today announced that its technology was featured in Digital Health, a leading source of industry healthcare technology news, published on 9th September 2019 . The article features an in-depth discussion on Cognetivity's proprietary technology, which can have a significant impact on healthcare providers' ability to diagnose dementia at an earlier stage than is currently practical using conventional approaches. In the article the company's CEO, Dr. Sina Habibi discusses the underlying scientific approach, utilizing leading-edge neuroscientific research, that is involved in the design of the company's Integrated Cognitive Assessment platform.

  • CNW Group

    Cognetivity Neurosciences Receives Key Chinese Patent Approval for its Proprietary Cognitive Assessment Platform

    The total number of people with dementia in China projected to reach 14.1 million by 2020 and 23.3 million by 2030. Annual cost of dementia expected to reach US$69B by 2020 and US$114B by 2030. OTCQB: CGNSF) announced today that it has received formal approval from the China National Intellectual Property Administration (CNIPA), for its patent covering the Company's unique system for assessing a mental health disorder in a human subject.

  • CNW Group

    Cognetivity Neurosciences' Chief Medical Officer to Present at Alzheimer's Association International Conference (AAIC) 2019

    OTCQB: CGNSF) announced today that it will join the world's leading scientific and clinical researchers, next generation investigators and clinicians and present key data from its Integrated Cognitive Assessment (ICA) at the 2019 Alzheimer's Association International Conference (AAIC). In a presentation titled 'The Integrated Cognitive Assessment – Employing Artificial Intelligence for the Detection of Cognitive Impairment' at 08:40 on July 16th , Cognetivity's Chief Medical Officer, Dr. Chris Kalafatis will present key highlights from the company's recent research and development program, alongside its use of advanced Artificial Intelligence (AI), which clearly demonstrate the ICA platform's high suitability for use as a clinical tool to improve the detection and earlier diagnosis of dementia.

  • CNW Group

    Cognetivity Neurosciences Selected to Present Groundbreaking New Research Data at the Alzheimer's Society Annual Conference 2019

    OTCQB: CGNSF) announced that it has been selected to present new results from its ongoing research into the use of the company's Integrated Cognitive Assessment (ICA) platform for the detection of early stage Alzheimer's disease at the Alzheimer's Society Annual conference 2019 at the Kia Oval, London on May 20th and 21st, 2019. In a poster titled 'Neural Speed of Visual Information Processing is Delayed in Early Stages of Alzheimer's Disease', Cognetivity's Chief Scientific Officer and Co-Founder, Dr. Seyed-Mahdi Khaligh-Razavi will present results detailing the ICA platform's ability to detect subtle changes in the temporal dynamics of brain activity in subjects with Mild Cognitive Impairment (MCI) and mild Alzheimer's disease (mild-AD).

  • CNW Group

    Cognetivity Neurosciences Appoints Digital Health Specialist to Drive Platform Commercialization Strategy & Sales

    OTCQB: CGNSF) announced today the appointment of digital health specialist, Rob Brougham as its Head of Commercial Development. Mr. Brougham is an astrophysicist by training with a successful 20-year commercial career in telecoms and digital healthcare in both blue chip and entrepreneurial roles. With a specialism in commercial acceleration, Rob has worked as a senior digital health advisor and consultant supporting both early-stage and multinational corporations, and brings a proven track record of delivering significant transactions worth over £1 billion.

  • CNW Group

    Cognetivity Neurosciences Selected to Present New Landmark Research Data at the 14th International Conference on Alzheimer's and Parkinson's Diseases in Lisbon, Portugal

    Cognetivity to present new, validated data demonstrating strong correleation with its ICA software test results and blood biomarkers associated with neurodegeneration. OTCQB: CGNSF) announced that it has been selected to present new, landmark results from its ongoing research into the use of the company's Integrated Cognitive Assessment platform for the detection of early stage cognitive impairment at the 14th international Conference on Alzheimer's and Parkinson's, March 26-31 , Centro de Congressos de Lisboa , Lisbon, Portugal . In posters titled 'Employing machine learning in the development of a self-administered, computerised cognitive assessment battery for the assessment of neurodegeneration' and "A brief language-independent and self-administered computerized test for cognitive assessment in multiple sclerosis", Cognetivity's Chief Medical Officer, Dr. Chris Kalafatis will present compelling new data from ongoing studies involving the company's unique AI-based approach which show positive results from trials into the effectiveness of its proprietary Integrated Cognitive Assessment (ICA) platform for early detection of neurodegeneration.

  • CNW Group

    Cognetivity Neurosciences Closes First Tranche of Non-Brokered Private Placement

    Each whole Warrant will entitle the holder to purchase an additional Share at a price of $0.55 for a period of 18 months from closing. If, commencing four months and one day after the date of issuance, the weighted average closing price of the Company's common shares is eaqual to or greater than $0.60 for 10 or more consecutive trading days (the "Acceleration Trigger"), the expiry date of the Warrants may be accelerated by the Company to the date that is 30 trading days after the date of a news release announcing the Acceleration Trigger.

  • CNW Group

    Cognetivity Neurosciences Secures Critical Quality Standard Certification

    Cognetivity Neurosciences Secures Critical Quality Standard Certification

  • CNW Group

    Cognetivity Neurosciences Announces Non-Brokered Private Placement

    The Private Placement will consist of the sale of up to 6,578,947 units (the "Units") at a price of $0.38 per Unit, each Unit consisting of one common share of the Company (a "Share") and one half common share purchase warrant (a "Warrant"). If, commencing on the date that is four months after the date of issue of the Warrants, the weighted average closing price of Company's common shares is equal to or greater than $0.60 for a period of 10 or more consecutive trading days (the "Acceleration Trigger"), the expiry date of the Warrants may be accelerated to the date that is 30 trading days after the date of a news release announcing the Acceleration Trigger.

  • CNW Group

    Cognetivity Neurosciences Publishes Key Results From its Integrated Cognitive Assessment Research in Nature Publishing Group Journal Scientific Reports

    OTCQB: CGNSF) today announced that results from its research and development program into its Integrated Cognitive Assessment (ICA) platform have been published in a leading peer-reviewed academic journal, Scientific Reports, from the publishers of Nature. The paper describes results from key studies validating the effectiveness of the ICA's unique approach of using a rapid visual categorization task for detecting changes in cognitive performance and its potential for use in early detection of mental disorders, including dementia, and micro-monitoring of cognitive performance.

  • ACCESSWIRE

    Three Companies Using AI and Innovation to Lead Healthcare Sector

    HOUSTON, TX / ACCESSWIRE / January 24, 2019 / Healthcare is quickly being disrupted by artificial intelligence. In fact, AI is quickly proving it can spot warning signs of disease before we're even aware of it ourselves. "Artificial intelligence could also use the way we look to help us predict future disease.

  • CNW Group

    Cognetivity Neurosciences Announced as 9th Industry Partner for Dementias Platform UK (DPUK)

    Cognetivity Neurosciences Announced as 9th Industry Partner for Dementias Platform UK (DPUK)

  • CNW Group

    Cognetivity Neurosciences Named as Young Company to Watch in 2019 on Forbes.com

    The article highlights the huge cost of treating dementia, the substantial cost-of-care savings generated by early detection and Cognetivity's use of artificial intelligence (AI) driven technology to improve diagnosis rates. Cognetivity's CEO and Director, Dr. Sina Habibi , commented: "2019 has got off to a great start, with Cognetivity being featured in Forbes as one of five young companies making an impact on the world to watch In 2019.

  • ACCESSWIRE

    The Most Innovative Healthcare AI Developments of 2019

    HOUSTON, TX / ACCESSWIRE / January 9, 2019 / Technology has changed in the blink of an eye. Concepts that were nothing more than science fiction, such as artificial intelligence (AI) and machine learning are now quickly disrupting global industries with significant capabilities. In fact, the limitless potential of AI alone is disrupting businesses, the way we conduct our affairs, and even the way financial institutions conduct high-frequency trading.